

Effectiveness-Implementation Hybrid Studies: An Overview and Reflection on 10 Years Since Their Introduction

Geoffrey M. Curran, PhD


Endowed Chair in Pharmacy Practice Innovation

Director, Center for Implementation Research

Professor, Departments of Pharmacy Practice and Psychiatry

University of Arkansas for Medical Sciences

Research Health Scientist, Central Arkansas Veterans Healthcare System



Goals for today

- Present on the hybrid study idea
 - From the perspective of their original conception...
 - Why and when to consider them
- Review 3 types of hybrid studies
- Present reflections from a recent working group
 - Chambers, Curran, Fernandez, Landes, McBain, Mittman, Pyne, Smith
 - Critique, adjustments, new recommendations...
 - *Under review*
- Take your questions

Who am I?

- Sociologist by training (1996)
- Began doing im



the US Department
RI)
plement
ants
s in support of adoption of EBPs
design in implementation

Think back to 2012...



NIH Public Access Author Manuscript

Med Care. Author manuscript; available in PMC 2013 August 01.

Published in final edited form as:

Med Care. 2012 March ; 50(3): 217–226. doi:10.1097/MLR.0b013e3182408812.

Effectiveness-implementation Hybrid Designs: Combining Elements of Clinical Effectiveness and Implementation Research to Enhance Public Health Impact

**Geoffrey M. Curran, PhD^{*}, Mark Bauer, MD[†], Brian Mittman, PhD[‡], Jeffrey M. Pyne, MD^{*},
and Cheryl Stetler, PhD[‡]**


^{*}Central Arkansas Veterans Healthcare System, and Department of Psychiatry, University of Arkansas for Medical Sciences, Little Rock, AR

[†]VA Boston Healthcare System, Harvard Medical School, Boston, MA

[‡]Center for Implementation Practice and Research Support (CIPRS), VA Greater Los Angeles Healthcare System, Los Angeles, CA


Traditional Research Pipeline

(...when do we do implementation research?)




- “Finish” efficacy research
- “Finish” effectiveness research
- Then start implementation research...

Traditional Pipeline as a relay race analogy: “Here... *GO! GO! GO!*”



Effectiveness-Implementation hybrid studies



Why Hybrid Studies?

- **Can we hurry up please?**
 - Blend intervention “effectiveness” and “implementation” research questions in the same study and save time
- **Don’t wait for “perfect” effectiveness data before moving to implementation research**
- **We can “backfill” effectiveness data while we test implementation strategies**
- **How do intervention outcomes relate to levels of adoption and fidelity?**
 - How will we know this without data from “both sides”?


Couple of intro thoughts about hybrids

- Researchers were doing “hybrid designs” well before my colleagues and I began speaking and writing about them as such
- 2012 paper tried to bring some clarity, direction, examples, and recommendations
- Original paper focused on trials but these hybrid concepts can and are being used in many other designs
 - *To me at the moment it's more about combining research questions*
 - More on this later...


When teaching this stuff, some very non-scientific language can also be helpful...

- The intervention/practice/innovation is **THE THING**
- Effectiveness research looks at whether **THE THING** works
- Implementation research looks at how best to help people/places **DO THE THING**
- *Implementation strategies* are the stuff we do to try to help people/places **DO THE THING**
- Main implementation outcomes are **HOW MUCH** and **HOW WELL** they **DO THE THING**

Types of Hybrids *by thing/do the thing*




Types of Hybrids *by thing/do the thing*




Hybrid Type 1: test
the *thing*, gather
information on
doing the *thing*

Types of Hybrids *by thing/do the thing*



Hybrid Type 3: test **do the thing**, gather information on the **thing**

Types of Hybrids *by thing/do the thing*



Hybrid Type 2: test
thing and *do the*
thing

Hybrid Type 1 (original spec)

Definition:

- Test the thing and explore implementation-related factors (80%/20%)

Description:

- Intervention effectiveness study “plus”:
 - Describe implementation experience (worked/didn’t; barriers/facilitators)
 - How might the thing need to be adapted going forward?
 - What is needed to support people/places to do the thing in the real world?

Indications:

- Intervention effectiveness evidence remains limited, so intensive focus on implementation might be premature...BUT
- Effectiveness study conditions offer ideal opportunity to explore implementation issues, plan implementation strategies for next stage

Remember...

- All effectiveness studies use “implementation strategies” to support the delivery of the intervention; we just usually don’t call them that...
- In clinical type studies, we “know” that some/many the strategies used are not feasible for supporting wide-spread adoption
 - Paying clinics, paying interventionists, paying for care, intensive training, frequent fidelity checks...
- BUT, we can learn from the use of those strategies during the study!

Type 1 examples

Contemporary Clinical Trials 43 (2015) 260–278

Contents lists available at ScienceDirect

Contemporary Clinical Trials

journal homepage: www.elsevier.com/locate/concltrial

 ELSEVIER



Research aimed at improving both mood and weight (RAINBOW) in primary care: A type 1 hybrid design randomized controlled trial[☆]

Jun Ma ^{a,b,*}, Veronica Yank ^b, Nan Lv ^a, Jeremy D. Goldhaber-Fiebert ^c, Megan A. Lewis ^d, M. Kaye Kramer ^e, Mark B. Snowden ^f, Lisa G. Rosas ^{a,b}, Lan Xiao ^a, Andrea C. Blonstein ^a

Lane-Fall et al. BMC Surgery 2014, 14:96
<http://www.biomedcentral.com/1471-2482/14/96>



CrossMark

STUDY PROTOCOL

Open Access

Handoffs and transitions in critical care (HATRICC): protocol for a mixed methods study of operating room to intensive care unit handoffs

Meghan B Lane-Fall^{1,2,3*}, Rinad S Beidas^{3,4}, Jose L Pascual^{5,6}, Meredith L Collard¹, Hannah G Peifer⁷, Tyler J Chavez⁸, Mark E Barry², Jacob T Gutsche¹, Scott D Halpern^{3,9,10}, Lee A Fleisher^{1,3,10} and Frances K Barg^{11,12}



BMC
Surgery



ADDICTION SCIENCE &
CLINICAL PRACTICE

Open Access

Hagedorn et al. Addiction Science & Clinical Practice 2014, 9:12
<http://www.ascpjournal.org/content/9/1/12>

RESEARCH

An implementation-focused process evaluation of an incentive intervention effectiveness trial in substance use disorders clinics at two Veterans Health Administration medical centers

Hildi J Hagedorn^{1,2,3*}, Cheryl B Stetler⁴, Ann Bangerter², Siamak Noorbaloochi^{2,3}, Maxine L Stitzer⁵ and Daniel Kivlahan^{6,7}

Bramoweth et al. Trials (2018) 19:73
DOI 10.1186/s13063-017-2437-y

Trials

STUDY PROTOCOL

Open Access



CrossMark

A hybrid type I trial to increase Veterans' access to insomnia care: study protocol for a randomized controlled trial

Adam D. Bramoweth^{1,2*}, Anne Germain³, Ada O. Youk^{1,4}, Keri L. Rodriguez^{1,5} and Matthew J. Chinman^{1,2,6}

Hybrid Type 2 (“original spec”)

Definition:

- Test thing and do the thing (50/50? 60/40? 72/28?)

Description:

- Dual-focus study:
 - Intervention effectiveness study combined with:
 - Implementation study of 2+ strategies (randomized?)
 - Study of single implementation strategy (not randomized; “pilot”)



Indications:

- Intervention effectiveness data available, though perhaps not for context/population of interest for this study
- Data on barriers and facilitators to implementation available

Study Considerations: Type 2

- Important to have an explicitly described implementation strategy that is thought to be plausible in the real world
 - Clear distinction from type 1
- Explicit measurement of adoption, fidelity...
 - Always happens in type 2
- Try to be clear about intervention components versus implementation strategy components
 - This isn't always easy to decide or describe
 - E.g., *delivery format*...
 - *Is delivering the intervention over the telephone an intervention component or an implementation strategy?*

Type 2 examples

TBM

ORIGINAL RESEARCH



CrossMark

Evaluating the effectiveness of physician counseling to promote physical activity in Mexico: an effectiveness-implementation hybrid study

Karla I. Galaviz,¹ Paul A. Estabrooks,² Edtna Jauregui Ulloa,³ Rebecca E. Lee,⁴ Ian Janssen,⁵ Juan López y Taylor,⁶ Luis Ortiz-Hernández,⁷ Lucie Lévesque⁸

Rich et al. BMC Public Health (2018) 18:29
DOI 10.1186/s12889-017-4584-1

BMC Public Health

Open Access



CrossMark

STUDY PROTOCOL
Implementation-effectiveness trial of an ecological intervention for physical activity in ethnically diverse low income senior centers

Porchia Rich^{1*} , Gregory A. Aarons², Michelle Takemoto¹, Veronica Cardenas³, Katie Crist¹, Khalisa Bolling¹, Brittany Lewars¹, Cynthia Castro Sweet⁴, Loki Natarajan^{1,3}, Yuyan Shi¹, Kelsie M. Full¹, Eileen Johnson¹, Dori E. Rosenberg⁵, Melicia Whitt-Glover⁶, Bess Marcus¹ and Jacqueline Kerr^{1,3}

Open Access

Protocol

BMJ Open Effectiveness of implementing a best practice primary healthcare model for low back pain (BetterBack) compared with current routine care in the Swedish context: an internal pilot study informed protocol for an effectiveness-implementation hybrid type 2 trial

Allan Abbott,¹ Karin Schröder,¹ Paul Enthoven,¹ Per Nilsen,² Birgitta Öberg¹



ADDICTION SCIENCE & CLINICAL PRACTICE

Rogers et al. Addiction Science & Clinical Practice 2013, 8:7
<http://www.ascpjournal.org/content/8/1/7>

STUDY PROTOCOL

Open Access

Telephone care coordination for smokers in VA mental health clinics: protocol for a hybrid type-2 effectiveness-implementation trial

Erin Rogers^{1,2*}, Senaida Fernandez⁸, Colleen Gillespie², David Smelson^{4,5}, Hildi J Hagedorn^{6,7}, Brian Elbel³, David Kalman^{4,5}, Alfredo Axtmayer¹, Karishma Kurowski^{1,2} and Scott E Sherman^{1,2}

Hybrid Type 3 (original spec)

Definition: Test do the thing, gather info on the thing (80%-20%...?)

Description:

- Largely focused on evaluating implementation strategies
- Unit of analysis = provider, clinic, or system
- Clinical outcomes are “secondary”

Indications:

- We sometimes proceed with implementation studies without completing a “full portfolio” of effectiveness studies
 - Strong momentum in a system, e.g., “We are rolling this out!”
- Interested in exploring how clinical effectiveness might vary by level/quality of implementation?

Study Considerations: Type 3

- How many places you got/need?
 - 6? 20? 40? 100?
- Which study design might work best for all involved?
 - cRCT? Stepped Wedge? Implementation Roll-Out Design?
 - See Brown, Curran, et al., 2017
 - Wolfenden et al., 2020 (trial designs)
- What's your evidence for implementation strategies selected?
- Clinical outcomes data collection
 - Measures available in existing data?
 - Primary data collection? (*Mental Health outcomes not routinely available...*)
 - Sub-sample?

More Type 3 examples

Spoelstra et al. *Implementation Science* (2019) 14:60
<https://doi.org/10.1186/s13012-019-0907-1>

Implementation Science

STUDY PROTOCOL

Open Access



Testing an implementation strategy bundle on adoption and sustainability of evidence to optimize physical function in community-dwelling disabled and older adults in a Medicaid waiver: a multi-site pragmatic hybrid type III protocol

Sandra L. Spoelstra^{1*} , Monica Schueler¹ and Alla Sikorskii²

Swindle et al. *Implementation Science* (2017) 12:90
DOI 10.1186/s13012-017-0624-6

Implementation Science

STUDY PROTOCOL

Open Access



A mixed methods protocol for developing and testing implementation strategies for evidence-based obesity prevention in childcare: a cluster randomized hybrid type III trial

Taren Swindle^{1*} , Susan L. Johnson², Leanne Whiteside-Mansell³ and Geoffrey M. Curran³

Kilbourne et al. *Implementation Science* 2014, 9:132
<http://www.implementationscience.com/content/9/1/132>



IMPLEMENTATION SCIENCE

STUDY PROTOCOL

Open Access

Protocol: Adaptive Implementation of Effective Programs Trial (ADEPT): cluster randomized SMART trial comparing a standard versus enhanced implementation strategy to improve outcomes of a mood disorders program

Amy M Kilbourne^{1,2*}, Daniel Almirall³, Daniel Eisenberg⁴, Jeanette Waxmonsky^{5,6}, David E Goodrich^{1,2}, John C Fortney⁷, JoAnn E Kirchner^{8,9}, Leif I Solberg¹⁰, Deborah Main¹¹, Mark S Bauer¹², Julia Kyle^{1,2}, Susan A Murphy^{3,3}, Kristina M Nord^{1,2} and Marshall R Thomas^{5,6}

Bauer et al. *Implementation Science* (2016) 11:22
DOI 10.1186/s13012-016-0385-7

Implementation Science

STUDY PROTOCOL


Open Access



Partnering with health system operations leadership to develop a controlled implementation trial

Mark S. Bauer^{1*} , Christopher Miller¹, Bo Kim¹, Robert Lew², Kendra Weaver³, Craig Coldwell⁴, Kathy Henderson⁵, Sally Holmes⁶, Marjorie Nealon Seibert⁶, Kelly Stolzmann⁶, A. Rani Elwy⁶ and JoAnn Kirchner⁵


2019 “intro to...” paper



Contents lists available at ScienceDirect

Psychiatry Research

journal homepage: www.elsevier.com/locate/psychres



An introduction to effectiveness-implementation hybrid designs

Sara J. Landes^{a,b,c,*}, Sacha A. McBain^{b,c}, Geoffrey M. Curran^{b,c,d}

^a The Department of Veterans Affairs Quality Enhancement Research Initiative (QUERI) for Team-Based Behavioral Health, 2200 Fort Roots Drive, North Little Rock, AR 72114, USA

^b South Central Mental Illness Research Education and Clinical Center (MIRECC), Central Arkansas Veterans Healthcare System, 2200 Fort Roots Drive, North Little Rock, AR 72114, USA

^c University of Arkansas for Medical Sciences, Department of Psychiatry, 4301 W. Markham St, Little Rock, AR 72205, USA


^d University of Arkansas for Medical Sciences, Department of Pharmacy Practice, 4301 W. Markham St, Little Rock, AR 72205, USA



Thoughts from 2019 paper

- Hybrid type 1 less of a “special case” but more routine?
 - If effectiveness research is the “last step” before trying to get people to do the thing... why not more of a focus on implementation questions?
 - Some folks doing hybrid 1 type work in *efficacy* research
 - Type 1 pilot studies
- Type 2 need to be fully justified and include “failsafe”
 - Build in time and data collection to iterate strategies if needed
- Hybrid type 3 less of a “special case” also?
 - When *wouldn’t* we want patient-level outcomes data?
 - Shouldn’t we PROVE how much fidelity is important and under what circumstances?

Thoughts from Oct 19, 2022...



Us and others reflecting...

- Special Issue on Hybrids in Frontiers in Health Services



- “Reflections on 10 Years of Effectiveness-Implementation Hybrid Studies”
 - In submission
 - Curran, Landes, McBain, Pyne, Smith, Fernandez, Chambers, Mittman
 - 5 questions

Q1: Are they really “designs”?

- *Depends on your definition...*
- BUT: Initial paper’s focus on trial designs was too limiting
 - Original paper talked about “where to randomize...”
 - “Do they have to be trials?” No.
 - Lots of folks took the basic idea and applied it to lots of study, program evaluation, QI, designs
- Let’s go with “**hybrid study**” instead

Q2: Which hybrid type should I use?

- Findings**
3. How much do you already know about implementation determinants for the intervention in your context of interest?
 - Not much? If you also need to focus on effectiveness data, consider type 1.
 - If the effectiveness data are strong, and you know enough already to develop/select a strategy or package of strategies to evaluate? Consider type 2 or 3.
 4. How ready are you to evaluate a “real world” implementation strategy or package of strategies?
 - Not ready? A type 1 is indicated, where you collect information on implementation determinants to help you prepare for developing strategies later.
 - Ready, and you need to focus as well on effectiveness of the intervention (Question 1)? Consider a type 2.
 - Ready, and your effectiveness data are strong (Question 1) and you don’t need to adapt a lot (Question 2)? Consider a type 3.

And remember...

- **You don't need to do a hybrid study**
- “Too early” for a hybrid?
 - Intervention not yet established as safe
- **Don't need to look at intervention effectiveness?**
 - Evaluating implementation of vaccines
 - Doing a focused study on implementation determinants
- **Explicitly justify why you are doing a hybrid**

Q3: Which research design should I use?

- Largely depends on the research questions...

- Research designs

- Type 1 studies
 - Type 3 studies
 - Type 2 studies

- See also other often used designs (series...)

And remember: your research design is only as good as your partners are comfortable with...

- Observational Types 2-3 in healthcare/public health systems evaluating roll outs
 - Pre-post formative work revising/optimizing strategies

Q4: What are challenges with the typology?

- Typology was set with clinical research mindset
 - Doesn't work so well for health promotion/public health type interventions
 - Little “efficacy”; Always start with “real world” implementation and strategies
 - Not sure types fit for policy research...
- “Shorthand” for relative focus on intervention/ implementation outcomes
 - Doesn't capture nuance
- Not everyone agrees on what “the thing” is
 - Medication adherence interventions
 - Contingency management interventions
- Still recommending use of typology...
 - But with language like “*consistent with type X*” when nuance is at play

Q5: How is cost analyzed in hybrids?

- Increasing attention paid to the cost of implementation strategies
- Not always easy to do: lotta time-based activity stuff
- Cost effectiveness analysis can be done in all hybrid types
 - Include implementation costs in conventional CEA
 - Focus of CE of implementation strategies on increments of adoption/fidelity
- Team sport for sure; seek professional help
- More and more examples published

Wrap it up

- We hope these thoughts and reflections are helpful to folks considering if/when/how to use hybrid studies
- Thanks for your attention!
- I am happy to take your questions/comments



Example of Type 1: CALM study

- Curran et al., 2012, *Implementation Science*
- Large effectiveness trial of anxiety intervention in primary care
 - 4 cities, 17 clinics, 1004 patients
 - Care managers using software tool with patients to navigate Tx manual
 - Care managers were local nurses/social workers already working in the clinics
- Qualitative process evaluation alongside trial
 - 47 interviews with providers, nurses, front office, and anxiety care managers
 - Most interviews done on the phone
 - Interview guide informed by an implementation framework (PARIHS)
 - (these days, that link needs to be very explicit...)

What did we learn?

- Lots of stuff...
- But, I'll share one important piece of data that illustrates the value of this kind of evaluation
 - Many of the providers in the participating clinics DID NOT refer a lot of patients for the trial. Some referred NOBODY.
 - Those who referred a lot were *already* interested in MH
 - Those who didn't were not persuaded during the site trainings that this was a good enough idea to be actively involved
 - So, "uptake" and "reach" were not great in the trial, even though the researchers tried to get all providers to refer
 - So, key barrier to future implementation was provider buy-in and engagement. "Standard" strategies to entice them didn't work.
 - We would have learned this about this barrier about 2+ years later if we had done this sequentially.

Type 2, Example 1: Cully et al., 2012, 2014+

- Clinical trial of brief cognitive behavioral therapy in treating depression and anxiety; 1 “pilot” implementation strategy
 - Patient randomization only; Pilot study of implementation strategy (online training, audit and feedback, facilitation) in 2 large VAMCs
 - Intent-to-treat analysis of clinical outcomes (N=320)
 - Feasibility, acceptability, and “preliminary effectiveness” data collected on implementation strategy
 - Measured knowledge acquisition, fidelity to model
 - Qualitative data on implementability, time spent, etc.
 - Preparatory to implementation trial of strategy

Type 2, Example 2: Garner et al., 2017

- Aim 1: effectiveness of a motivational interviewing-based brief intervention (MIBI) for substance use as an adjunct to usual care (referral) within AIDS service organizations (ASOs)
- Aim 2: effectiveness of implementation and sustainment facilitation (ISF) as an adjunct to the Addiction Technology Transfer Center (ATTC) model for training staff in MI
 - Patients randomized within ASOs (N=1872)
 - Substance use outcomes
 - ASOs randomized to ACCT or ACCT+ISF (N=39)
 - Proctor et al (2011) implementation outcome measures

Type 3 Example, Smelson et al., 2015

- Mission-Vet is an evidence-based treatment for co-occurring SUD and MH disorders among homeless Veterans
- Compare “implementation as usual” of Mission-Vet to IAU plus Getting To Outcomes (GTO)
 - IAU = Standard training plus access to Mission-Vet manual
 - GTO = planning, implementation (supervision, monitoring...), self evaluation (audit and feedback)
- 3 large VAMCs
 - Case managers (69) randomized to IAU or IAU+GTO
 - 1500-2000 Veterans
- RE-AIM measures
 - Adoption = meeting 50% of eligible Veterans involved in intervention
 - Effectiveness = SUD, MH symptoms, functioning, housing